IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News / Institutional news

  • 25/07/2022 - Institutional news

    30 years of the Olympic Anti-Doping Laboratory

    Monday 25 July marks the 30th anniversary of the inauguration of the Barcelona Olympic Games, which represented a historic milestone for the city. During this great event, the Anti-Doping Laboratory of the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) was entrusted with the anti-doping controls of the athletes at both the Barcelona 92 Olympic and Paralympic Games. The laboratory was set up in 1985 as part of the Barcelona Olympic bid. Its designation as an Olympic laboratory allowed the modernization of the facilities and equipment of both the laboratory itself and the IMIM. The laboratory took up anarea of 1100 m2, and during the Games it worked 24 hours a day. In total, close to 110 people were involved in the anti-doping work, considering the laboratory staff, guest scientific staff, volunteers and support staff.

    Més informació "30 years of the Olympic Anti-Doping Laboratory"

  • 03/02/2022 - Institutional news

    The Catalonian Anti-doping Laboratory is collaborating with the Olympic Laboratory in Beijing

    On 4 February, the XXIV Olympic Winter Games will be inaugurated in Beijing, which this year will be held under very strict COVID-19 control protocols. Three scientists from the IMIM Anti-Doping Laboratory, Rosa Ventura, Sergi Coll and Lídia Requena, will be travelling to Beijing to work in the Olympic laboratory. Rosa Ventura will be involved in the management and supervision group, Sergi Coll will be working on the detection of anabolic steroids, and Lídia Requena will be concentrating on the detection of hormones (erythropoietin, growth hormone). The Beijing Laboratory will analyse 3000 samples over the Olympic Games and another 600 during the Paralympic Games. This high volume of samples requires a great deal of analytical equipment and a large number of specialised professionals organised into shifts working around the clock. 

    Més informació "The Catalonian Anti-doping Laboratory is collaborating with the Olympic Laboratory in Beijing"

  • 22/12/2021 - Institutional news

    Research by the Catalonian Anti-Doping Laboratory is the basis for the World Anti-Doping Agency's new rules on the use of glucocorticoids in sport

    From 2022, the World Anti-Doping Agency's (WADA) list of prohibited substances and methods in sport is to include important changes regarding the use of glucocorticoids in sport. From this point on, all injectable methods will be prohibited during competitions, in addition to oral and rectal administration. Other ways of receiving the medication, such as via inhalation, intranasal or dermatological routes, will continue to be permitted if their use is necessary for therapeutic reasons. There will still be no restrictions on the use of glucocorticoids in out-of-competition periods. Criteria have also been defined to improve the safety of glucocorticoid administration for therapeutic reasons. Firstly, the distinction between prohibited and permitted routes of administration has been improved by defining a specific information concentration for each glucocorticoid. Secondly, blanking periods after prohibited treatments have been defined so that those performed in out-of-competition periods close to competitions do not lead to false positive results in samples collected during competitions.

    Més informació "Research by the Catalonian Anti-Doping Laboratory is the basis for the World Anti-Doping Agency's new rules on the use of glucocorticoids in sport"

  • 22/12/2021 - Institutional news

    Dr. Marta Torrens will be part of the executive committee of the World Association on Dual Disorders.

    The Director of the Addictions Process at INAD and researcher at the Hospital del Mar Medical Research Institute becomes a member of the executive committee of this organization that promotes knowledge and research on dual pathology. The congress of the World Association on Dual Disorders (WADD) approved at its congress, held in Paris between December 7 and 9, the incorporation of Dr. Marta Torrens to its executive committee. Thus, the Director of the Addictions Process of the Institute of Neuropsychiatry and Addictions of the Hospital del Mar (INAD) and coordinator of the Addictions Research Group of the Hospital del Mar Medical Research Institute (IMIM), will participate in the organization's decision-making, such as the organization of congresses, training courses and publications.

    Més informació "Dr. Marta Torrens will be part of the executive committee of the World Association on Dual Disorders."

  • 03/12/2021 - Institutional news

    1,880,000 to prepare reference materials to assess the quality of accredited anti-doping laboratories around the world

    The Hospital del Mar Medical Research Institute (IMIM) has signed a five-year contract with the World Anti-Doping Agency (WADA, https://www.wada-ama.org/ ), within the framework of a tender of offers at an international level, worth € 1,880,000, for the preparation of reference materials for its external quality assessment program of laboratories (EQAS) accredited to carry out anti-doping control around the world (WADA's External Quality Assessment Scheme). Dr. Oscar Pozo, group leader of the Applied Metabolomics Research Group of the Neurosciences Research Program at IMIM, will be responsible for the execution of the contract as of January 2022.

    Més informació "1,880,000 to prepare reference materials to assess the quality of accredited anti-doping laboratories around the world"

  • 23/11/2020 - Institutional news

    The BAPP renews its TECNIO accreditation

    The BAPP (Bioanalysis, Proteomics and Pharmacology), a collaborative centre from the Hospital del Mar Medical Research Institute (IMIM) and the UPF, has obtained the TECNIO accreditation for the period 2020-2023.  This seal, which the centre had already obtained in previous editions, is awarded by the Government of Catalonia through ACCIÓN. It identifies and raises the profile of centres with high scientific and technical capacities that are considered to be developers of differential technologies and which are leaders when it comes to transferring their knowledge and technologies to industry. The BAPP is a multidisciplinary centre specialising in research and service activities in four sectors: pharmacology, neurosciences, peptide chemistry, and bioanalysis. Its main focus is the development of new drugs for human and veterinary use.  It comprises the Integrated Pharmacology and Systems Neuroscience (Farmacologia Integrada i Neurociència de Sistemes; FINS) research group of the IMIM-Hospital del Mar, on the one hand, and the Proteomics and Protein Chemistry research group from the UPF on the other.

    Més informació "The BAPP renews its TECNIO accreditation"

  • 24/07/2020 - Institutional news

    IMIM, one of the Health Research Institutes to receive an ISCIII Responsible Research and Innovation Award

    In the first edition of the Responsible Research and Innovation (RRI) in Health Awards organised by ISCIII and promoted as part of the European project ORION  (Open Responsible research and Innovation to further Outstanding kNowledge) three proposals from three different Health Research Institutes (HRI) have been honoured out of a total of 26 proposals received. One of these three proposals is an IMIM project: The name of the successful project is "Co-creation and citizen participation in the design of the PENSA Study on the Prevention of Cognitive Impairment in People with Subjective Memory Complaints". Presented by Natàlia Soldevila and Laura Forcano from the Integrated Pharmacology and Systems Neuroscience research group at the IMIM, this work stands out for its application of citizen participation in the design of a clinical trial, an added value that allows the project to be reoriented to better adapt to the needs and expectations of the participants.

    Més informació "IMIM, one of the Health Research Institutes to receive an ISCIII Responsible Research and Innovation Award"

  • Institutional news

    The IMIM becomes part of the European Consortium EATRIS to promote translational medicine

    The IMIM Clinical Metabolomics Platform led by Dr. Oscar J. Pozo, from the IMIM Integrated Pharmacology and Systems Neuroscience Research Group, has become part of the EATRIS consortium, the European infrastructure for translational medicine, as part of the biomarker platform. This means that the IMIM is now part of a consortium comprising more than 80 prestigious European institutes that is aiming to establish synergies between healthcare researchers by providing them with the most advanced technologies and the experience needed to make headway in translational medicine. EATRIS is a European Research Infrastructure Consortium (ERIC) whose main objective is to advance translational medicine.  Translational research is a highly multidisciplinary and complex undertaking.  One of the greatest challenges in innovation is to understand which steps are necessary and the most appropriate technology and knowledge for taking these steps.

    Més informació "The IMIM becomes part of the European Consortium EATRIS to promote translational medicine"

  • 09/10/2015 - Institutional news

    IMIM receives funding from the IOC to conduct innovative anti-doping research

    In its mission to protect and promote clean athletes, the International Olympic Committee (IOC) is financing and backing seven innovative research projects in the fight against doping, which include a project by Dr Jordi Segura, coordinator of the research group on bioanalysis and analytic services at IMIM. The project is entitled ‘Developments for improving compliance with blood testing, a fundamental but minimally implemented tool in doping control (EASY BLOOD)’ and its purpose is to explore and validate the applicability of the use of new matrices (dried blood spot and capillary sampling) to replace the blood sample collection methods that are currently used to control doping (which are whole blood, plasma and serum). The seven projects funded are from Australia, Spain and the United Kingdom and were selected from among the applications received from throughout the world in the two calls opened by the IOC.

    Més informació "IMIM receives funding from the IOC to conduct innovative anti-doping research"

  • 20/12/2012 - Institutional news

    A delegation from the China Anti-Doping Agency visits IMIM

    On Friday the 14th of December, the Bioanalysis and Analytical Services Research Group from IMIM (Hospital del Mar Medical Research Institute) was visited by a delegation from the China Anti-Doping Agency (CHINADA). This visit is framed within the longstanding collaboration between the Anti-Doping Control Laboratory and IMIM and the Beijing Anti-Doping Laboratory and the China Anti-Doping Agency for research projects on doping control in sports.

    Més informació "A delegation from the China Anti-Doping Agency visits IMIM"

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact